SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Dianthus Therapeutics reports Q3 revenue of $1.21M

DNTH
SquawkNews Desk 1 updates Updated Nov 04, 2026, 09:14 PM UTC

Story updates

09:14:30 PM UTC
SquawkNews
Dianthus Therapeutics reported third-quarter 2026 revenue of $1.21M, up 205.6% from $396K a year earlier, as reimbursable clinical-trial costs increased. Net loss widened to $46.6M from $36.8M, while loss per share narrowed to $0.81 from $0.97.Financial HighlightsBusiness HighlightsOriginal SEC Fil…

Related stories

MetLife Q3 Net Income Rises to $2.397 Billion MetLife reported third-quarter 2026 net income of $2.397 billion, up from $896 million a year earlier, alongside revenue growth. M impact | EQUITY | Nov 04, 2026, 10:11 PM UTC Great Elm Group Q1 Revenue Drops on Property Sale Timing Great Elm Group reported lower Q1 revenue, citing the timing of property sales. M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC Vaxcyte Q3 Loss Smaller Than Estimates; Plans VAX-31 Filing in H1 2028 Vaxcyte reported a Q3 loss smaller than estimates and plans to file VAX-31 in the first half of 2028. M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC Mercado Libre Q3 Revenue and Financial Income Rise 45% to $10.75 Billion Mercado Libre reported third-quarter net revenue and financial income of $10.75 billion, up 45% year over year. Brazil delivered the strongest growth. M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC Genworth Financial Posts Q3 Net Loss on Closed Block Weakness Genworth Financial reported a third-quarter net loss, citing weakness in its Closed Block segment. M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC B2Gold Reports Q3 Results, Lowers Annual AISC Guidance B2Gold lowered its annual all-in sustaining cost guidance and said it remains on track to achieve production guidance. M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC